2097 related articles for article (PubMed ID: 16955068)
1. Anticancer activities of histone deacetylase inhibitors.
Bolden JE; Peart MJ; Johnstone RW
Nat Rev Drug Discov; 2006 Sep; 5(9):769-84. PubMed ID: 16955068
[TBL] [Abstract][Full Text] [Related]
2. Development of histone deacetylase inhibitors for cancer treatment.
Marchion D; Münster P
Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177
[TBL] [Abstract][Full Text] [Related]
3. Protein deacetylases: enzymes with functional diversity as novel therapeutic targets.
Yoshida M; Shimazu T; Matsuyama A
Prog Cell Cycle Res; 2003; 5():269-78. PubMed ID: 14593721
[TBL] [Abstract][Full Text] [Related]
4. HDAC inhibitors for the treatment of cancer.
Secrist JP; Zhou X; Richon VM
Curr Opin Investig Drugs; 2003 Dec; 4(12):1422-7. PubMed ID: 14763127
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.
Carew JS; Giles FJ; Nawrocki ST
Cancer Lett; 2008 Sep; 269(1):7-17. PubMed ID: 18462867
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylation in epigenetics: an attractive target for anticancer therapy.
Mai A; Massa S; Rotili D; Cerbara I; Valente S; Pezzi R; Simeoni S; Ragno R
Med Res Rev; 2005 May; 25(3):261-309. PubMed ID: 15717297
[TBL] [Abstract][Full Text] [Related]
7. HDAC inhibitors: a potential new category of anti-tumor agents.
Pan LN; Lu J; Huang B
Cell Mol Immunol; 2007 Oct; 4(5):337-43. PubMed ID: 17976313
[TBL] [Abstract][Full Text] [Related]
8. Acetylation of proteins as novel target for antitumor therapy: review article.
Di Gennaro E; Bruzzese F; Caraglia M; Abruzzese A; Budillon A
Amino Acids; 2004 Jul; 26(4):435-41. PubMed ID: 15290351
[TBL] [Abstract][Full Text] [Related]
9. Role of histone deacetylase inhibitors in the treatment of cancer (Review).
Mei S; Ho AD; Mahlknecht U
Int J Oncol; 2004 Dec; 25(6):1509-19. PubMed ID: 15547685
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in the discovery of small molecule histone deacetylase inhibitors.
Remiszewski SW
Curr Opin Drug Discov Devel; 2002 Jul; 5(4):487-99. PubMed ID: 12197307
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of histone deacetylases: a new strategy to target epigenetic modifications for anticancer treatment.
Weidle UH; Grossmann A
Anticancer Res; 2000; 20(3A):1471-85. PubMed ID: 10928059
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylases and cancer: causes and therapies.
Marks P; Rifkind RA; Richon VM; Breslow R; Miller T; Kelly WK
Nat Rev Cancer; 2001 Dec; 1(3):194-202. PubMed ID: 11902574
[TBL] [Abstract][Full Text] [Related]
14. The molecular mechanism of HDAC inhibitors in anticancer effects.
Bi G; Jiang G
Cell Mol Immunol; 2006 Aug; 3(4):285-90. PubMed ID: 16978537
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors: biology and mechanism of action.
Mehnert JM; Kelly WK
Cancer J; 2007; 13(1):23-9. PubMed ID: 17464243
[TBL] [Abstract][Full Text] [Related]
16. FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities.
Konstantinopoulos PA; Vandoros GP; Papavassiliou AG
Cancer Chemother Pharmacol; 2006 Nov; 58(5):711-5. PubMed ID: 16435156
[TBL] [Abstract][Full Text] [Related]
17. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
[TBL] [Abstract][Full Text] [Related]
18. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer.
Johnstone RW
Nat Rev Drug Discov; 2002 Apr; 1(4):287-99. PubMed ID: 12120280
[TBL] [Abstract][Full Text] [Related]
19. Identification of type-specific anticancer histone deacetylase inhibitors: road to success.
Noureen N; Rashid H; Kalsoom S
Cancer Chemother Pharmacol; 2010 Sep; 66(4):625-33. PubMed ID: 20401613
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors for epigenetic therapy of cancer.
Monneret C
Anticancer Drugs; 2007 Apr; 18(4):363-70. PubMed ID: 17351388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]